Navigation Links
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: POZEN Announces Positive Outcome for Proof Concept Study
(Date:6/2/2015)... June 2, 2015 The American Society of ... Practice Guideline for the Use of Medications in the ... ).  The Practice Guideline will assist clinicians ... use. It addresses knowledge gaps about the benefits of ... evidence-based coverage standards by payers. The ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. The delivery of drugs ... in the treatment of neurological disorders. Drugs may ... systematically (e.g., by intravenous injection) for targeted action ...
(Date:6/2/2015)... and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ) has announced the addition of ... report to their offering. The report provides ... , Japan , Europe ... , and Rest of World. This report ... Million by the following Product Segments: Stapler Products (Internal Stapler, ...
Breaking Medicine Technology:American Society of Addiction Medicine Releases National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use 2American Society of Addiction Medicine Releases National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use 3Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3Surgical Incision Closures - Global Strategic Business Report 2015 2
... May 5 A voluntary recall has,been issued ... and,labeled with the Cardinal Health brand name. Hydrox ... individual mouthwash bottles and,those contained within Cardinal Health ... and been found positive for Burkholderia,cepacia (B. cepacia). ...
... Delivered Within Pre-Determined ... and Standard Dosing Limitations, BRIDGEWATER, N.J., May 5 ... SoloSTAR(R) disposable insulin pen,prefilled with Lantus(R) (insulin glargine [rDNA ... the pens,accurately delivered all insulin doses within standard limits ...
Cached Medicine Technology:Hydrox Inc., Cardinal Health Issue Nationwide Recall of Alcohol-Free Mouthwash For Hospitals 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:6/2/2015)... 02, 2015 On Wednesday, May 27, 2015, ... to a top speed of 207.9 mph. In the ... to break the 200 mph mark. Jay Leno was ... upcoming episode of Jay Leno’s Garage, which will air on ... the 8.5 mile high speed oval at the Continental Tire ...
(Date:6/2/2015)... UCLA Health and Exer have completed ... and expand urgent care services in Los Angeles County. ... University of California Board of Regents and the Exer ... Health to purchase a minority share of four existing ... Park and Northridge and creates opportunity to grow and ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 TMG Health, ... for health plans in the Medicare Advantage, Medicare Part ... a sponsor and exhibitor at AHIP’s Institute 2015, the ... Insurance Plans. The conference will be held June 3-5 ... #1303, will offer opportunities for attendees to schedule private ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 On October ... congressional efforts for another delay. , On Monday, ... Health Subcommittee for the House Ways and Means Committee, ... to Centers for Medicare and Medicaid Services, urging the ... as CMS rolls out ICD-10. ICD-10 is the newest ...
(Date:6/2/2015)... 02, 2015 IMPAK Corporation, a ... has announced the availability of “child-resistant” pouches and ... by children, especially curious toddlers. The Child Resistant ... tested to CFR 1700.20 protocols. The announcement was ... Looks Like Candy, “With the proliferation of consumer ...
Breaking Medicine News(10 mins):Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... , , CHADDS FORD, Pa., Aug. 31 ... at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, ... review the company,s products and development programs. , , The ... www.endo.com under the investors section. , ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... say , MONDAY, Aug. 31 (HealthDay News) -- Mass screening ... has led to mass over-diagnosis and over-treatment, a new study ... in 1986, federal government data show that the number of ... said the report in the Aug. 31 online issue of ...
... , MONDAY, Aug. 31 (HealthDay News) -- Walk-in retail clinics ... a new study has found. , Writing in the Sept. ... study author Dr. Ateev Mehrotra said that retail clinics -- ... drug stores and other retail chain stores such as Target ...
... , ABBOTT PARK, Ill., Aug. 31 ... Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009. ... will make a presentation on the company at 8:10 a.m. Central ... the presentation will be accessible through Abbott,s Investor Relations Web site ...
... , Safety tips also offered as fires threaten ... The American Red Cross is on the scene offering evacuees a safe ... and scorch thousands of acres. Overnight, nearly 200 people took refuge from ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: